The current report, like the prior version, compares prices for different categories of drug products, including brand-name originator drugs, unbranded generic drugs, biologics, and nonbiologic drugs. This report adds new analyses on biosimilar price comparisons and on changes in price comparison findings over time. This research was funded by the U.S. Department of Health and Human Services Office of the Assistant Secretary for Planning and Evaluation under Contract No. HHSP23320095649WC-TO38, and the update was funded under Contract No. HHSP233201500038I and carried out within the Payment, Cost, and Coverage Program in RAND Health Care.RAND Health Care, a division of the RAND Corporation, promotes healthier societies by improving health care systems in the United States and other countries. We do this by providing health care decisionmakers, practitioners, and consumers with actionable, rigorous, objective evidence to support their most complex decisions. For more information, see www.rand.org/health-care, or contact